Less aquaporin-4 in astrocytes surrounding blood vessels suggests impaired clearance of Aβ in people with AD.
In a PD mouse model, microbes pump out short-chain fatty acids that worsen synuclein aggregation and motor problems. Intestinal flora from people appears to do the same.
Enhancing glutamate transport partially restores neural function in mice.
PET scans detect activated glial cells in current and recently retired professional football players up to 21 years after their last concussion.
Friends and colleagues grapple with the loss of this young investigator.
Insulin delivered directly to the brain does nothing to Aβ in an AD mouse model, complicating the relationship between diabetes and Alzheimer’s.
Evidence from a nationally representative sample suggests a 12-year drop in age-specific risk of dementia.
Eli Lilly has given up on regulatory submission for mild AD, but leaves door open to seeking approval for earlier disease stages if three ongoing studies succeed.
Strains injected into mouse brain seed tau aggregation at different rates and in different regions of the brain.
Using a new, quantitative MRI method, researchers find accelerated myelin deterioration in preclinical Alzheimer’s disease.
This new inhibitor, which only works once phosphorylated by GSK3, reduced amyloid load and prevented cognitive deficits in an AD mouse model.
At least one phosphate tag may quell Aβ excitotoxicity.
As intestinal flora go about their business of digesting food and regulating immune responses, might they unwittingly accelerate Parkinson’s? In transgenic mice that are genetically susceptible to the disease, microbiota accelerated synuclein pathology in the brain as well as motor problems, according to a new study. Short-chain fatty acids pumped out by the microbes ramped up neuroinflammation in the animals’ brains, and appear to somehow exacerbate the disease. Strikingly, gut microbes derived from people with PD and transferred into the mice precipitated symptoms even faster. Researchers now aim to figure out how these microbial shenanigans in the gut cause disease in the brain.
On the morning of November 23, Eli Lilly and Co. announced that the immunotherapy solanezumab had missed the primary endpoint in the EXPEDITION3 trial. This study had enrolled 2,100 people at 198 sites across the world who had mild Alzheimer’s disease ascertained by way of a positive florbetapir scan. Lilly will not pursue regulatory approval of solanezumab to treat mild AD; however, it appears at the moment that earlier-stage trials in prodromal, preclinical, or primary prevention populations are continuing. According to Lilly, results in primary and secondary outcomes were trending in the direction of a treatment benefit, but the effects were small.
Are we humans alone in developing Alzheimer’s disease? Other primates and even dogs accumulate amyloid plaques as they age, but seem surprisingly resistant to neurofibrillary tangles, neurodegeneration, and full-blown dementia. What sets us apart from other animals, and what can we learn from their resilience? Join Lary Walker, Marc Dhenain, Elizabeth Head, Patrick Hof, Cynthia Lemere, and Peter Nelson for an Alzforum Webinar on Wednesday, December 7, at 12 p.m. U.S. Eastern time.
- William Rosenblum on Lilliputian Effect Size Fells Phase 3 Trial of Solanezumab, Leaving Its Future Uncertain
- Ron Louie on Lilliputian Effect Size Fells Phase 3 Trial of Solanezumab, Leaving Its Future Uncertain
- Angel Golimstok on Lilliputian Effect Size Fells Phase 3 Trial of Solanezumab, Leaving Its Future Uncertain
- Anna-Leena Sirén on In NFL Players, Brain Inflammation May Persist Years After Head Trauma
- M. Paul Murphy on Field Loses Chad Dickey, 40, to Cancer
- Susan Nyland on Field Loses Chad Dickey, 40, to Cancer
- Javier Moron-Oset on Is Tau Phosphorylation All Bad?
- Yipeng Wang on Is Tau Phosphorylation All Bad?
- Rohan de Silva on Field Loses Chad Dickey, 40, to Cancer
- Joe Abisambra on Field Loses Chad Dickey, 40, to Cancer
- Jada Lewis on Field Loses Chad Dickey, 40, to Cancer
- Donna M. Wilcock on Field Loses Chad Dickey, 40, to Cancer
- Leigh Hochberg on Moving Toward Independence: Paralyzed Woman ‘Talks’ via Brain Implant
- Andreana Benitez on Imaging Myelin: Shining a Light on Early Alzheimer’s Pathology?
- Karen Duff on More Evidence That Distinct Tau Strains May Cause Different Tauopathies
- Manuela Neumann on ALS-FTD Mouse Model Develops Motor Neuron Disease
- Mark Verheijen on ALS-FTD Mouse Model Develops Motor Neuron Disease
- Khalid Iqbal on Is Tau Phosphorylation All Bad?
- Bruno Pietro Imbimbo on Lilliputian Effect Size Fells Phase 3 Trial of Solanezumab, Leaving Its Future Uncertain
- Carol Brayne on U.S. Dementia Rates Fall
- Sudha Seshadri on U.S. Dementia Rates Fall